Jeffrey L Silber
Overview
Explore the profile of Jeffrey L Silber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
532
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bloom P, Bassis C, Crossette E, Silber J, Norman J, Young V, et al.
Hepatol Commun
. 2025 Feb;
9(3).
PMID: 39969428
Background: Novel therapies are needed to treat HE, and microbiome modulation is a promising target. VE303 is a defined consortium of 8 purified, clonal bacterial strains, known to produce metabolites...
2.
Menon R, Bhattarai S, Crossette E, Prince A, Olle B, Silber J, et al.
Nat Med
. 2025 Jan;
31(1):223-234.
PMID: 39747680
Donor-derived fecal microbiota treatments are efficacious in preventing recurrent Clostridioides difficile infection (rCDI), but they have inherently variable quality attributes, are difficult to scale and harbor the risk of pathogen...
3.
Louie T, Golan Y, Khanna S, Bobilev D, Erpelding N, Fratazzi C, et al.
JAMA
. 2023 Apr;
329(16):1356-1366.
PMID: 37060545
Importance: The effect of rationally defined nonpathogenic, nontoxigenic, commensal strains of Clostridia on prevention of Clostridioides difficile infection (CDI) is unknown. Objective: To determine the efficacy of VE303, a defined...
4.
DSouza M, Menon R, Crossette E, Bhattarai S, Schneider J, Kim Y, et al.
Cell Host Microbe
. 2022 Apr;
30(4):583-598.e8.
PMID: 35421353
Manipulation of the gut microbiota via fecal microbiota transplantation (FMT) has shown clinical promise in diseases such as recurrent Clostridioides difficile infection (rCDI). However, the variable nature of this approach...
5.
Russell A, Parrino J, Fisher Jr C, Spieler W, Stek J, Coll K, et al.
Vaccine
. 2015 May;
33(27):3129-34.
PMID: 25964168
Background: This randomized, placebo-controlled study assessed the safety, tolerability, and immunogenicity of live virus zoster vaccine (ZV) in individuals receiving chronic/maintenance systemic corticosteroid therapy (daily dose equivalent of 5-20mg prednisone)...
6.
Morrison V, Oxman M, Levin M, Schmader K, Guatelli J, Betts R, et al.
J Infect Dis
. 2013 May;
208(4):559-63.
PMID: 23633406
Background: After completion of the Shingles Prevention Study (SPS; Department of Veterans Affairs Cooperative Studies Program Number 403), SPS participants who had initially received placebo were offered investigational zoster vaccine...
7.
Tyring S, Stek J, Smith J, Xu J, Pagnoni M, Chan I, et al.
Clin Vaccine Immunol
. 2012 Jul;
19(9):1411-5.
PMID: 22787198
Varicella-zoster virus (VZV)-specific cell-mediated immunity (CMI) responses were compared over time following an episode of herpes zoster (HZ) with those of age-, race-, and gender-matched healthy controls (HC) without HZ,...
8.
Vermeulen J, Lange J, Tyring S, Peters P, Nunez M, Poland G, et al.
Vaccine
. 2011 Dec;
30(5):904-10.
PMID: 22154769
Background: Incidence and severity of herpes zoster (HZ) and postherpetic neuralgia increase with age, associated with age-related decrease in immunity to varicella-zoster virus (VZV). One dose of zoster vaccine (ZV)...
9.
Diaz-Mitoma F, Halperin S, Tapiero B, Hoffenbach A, Zappacosta P, Radley D, et al.
Vaccine
. 2010 Dec;
29(6):1324-31.
PMID: 21134456
The current recommended infant vaccination schedules require many injections at multiple sites, which increase stress for infants and parents and may create challenges to vaccination compliance. Therefore, combination vaccines, which...
10.
MacIntyre C, Egerton T, McCaughey M, Parrino J, Campbell B, Su S, et al.
Hum Vaccin
. 2010 Oct;
6(11):894-902.
PMID: 20980796
This study evaluated safety & immunogenicity of ZOSTAVAX® (zoster vaccine: ZV) administered concomitantly versus nonconcomitantly with PNEUMOVAX® 23 (pneumococcal vaccine: PPV23). This randomized, double-blind, placebo-controlled study enrolled 473 subjects ≥60...